Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Polycystic Ovary Syndrome 3Neoplasms 2Obesity 1Leukemia, Myeloid, Acute 1Hyperandrogenism 1Heart Failure 1Critical Illness 1Cardiotoxicity 1Acute Kidney Injury 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Neoplasms × Spironolactone × Clear all
NCT06005259 2023-08-22

SPIROTOX

University of Sao Paulo

Phase 4 Unknown
264 enrolled

Heart Failure, Neoplasms, Cardiotoxicity

NCT02531412 2017-01-04

SPIROCAN

Instituto Nacional de Cancerologia de Mexico

Phase 2/3 Unknown
24 enrolled
Genitourinary

Neoplasms, Critical Illness, Acute Kidney Injury

Data powered by HemOnc (CC BY 4.0) Colophon âš¡